Redeye sees Q2 sales in line with our forecast but higher costs, prompting us to lower our 2024e EBI...
Redeye leaves its initial take on Xbrane following this mornings news that Xbrane has regained the f...
Q2 production slightly below Focus in Q2: Exploration, FDP on Block 56 & strategic review P/NAV of 0...
Q2e: 4.0m EEs, 58k SCs pre-announced, expect SEK 13m EBIT Cut sales by ~4%, EBIT by ~6% on lower EE ...
Redeye updates its estimates on Sleep Cycle following its Q2 2024 quarterly report, which matched ou...
Q2e: one eMELT-iD and two Freemelt ONE deliveries Sales of SEK 13.
Suominen’s Q2 results are due Aug 9. H1 has low comparison figures, while H2 should also have scope ...
Etteplan publishes its Q2/24 figures on 8th of August.
Føroya Banki reports its Q2 2024 results on 1 August 2024.
Overall demand weakness, combined with customer-specific problems, led Scanfil to downgrade its 2024...
Redeye shares its initial comments on Xspray following the Dasynoc CRL.
Addlife har en solid position inom en bransch med stabil och ökande efterfrågan.
Redeye anticipates a muted Q2 2024 in terms of quarter-on-quarter growth, though stable ARR growth i...
Redeye is hoping for a swift and robust solution to OXE Marine’s financial predicament.
Redeye is happy to see that Impact Coatings has received another order for an IC2000 fuel cell coati...
Redeye ger en kort kommentar om det negativa utlåtandet från CHMP.
Sales down 20% y-o-y in Q2 More restructuring in the quarter Overall market has likely trouged Q2: ...
- Profitability yet to improve - Extrem Borr och Sågteknik added to numbers - Positive revision main...
Redeye leaves a note following Alzinova’s announcement of Carol Routledge having been appointed as t...
Net sales and adjusted EBIT were close to market consensus (LSEG) in Q2.
